CORDIS
EU research results

CORDIS

English EN
European AIDS Vaccine Initiative 2020

European AIDS Vaccine Initiative 2020

Objective

HIV-1 is responsible for a global pandemic of 35 million people, and continues to spread at a rate of >2 million new infections/year. It is widely acknowledged that a protective vaccine would be the most effective means to reduce HIV-1 spread and ultimately eliminate the pandemic, while a therapeutic vaccine may help mitigate the clinical course of disease and lead to strategies of viral eradication. However despite 30 years of research, we do not have a vaccine capable of protecting from HIV-1 infection or impacting on disease progression. This in part represents the challenge of identifying immunogens and vaccine modalities with reduced risk of failure in late stage development. To overcome this bottleneck some of the most competitive research groups in vaccine discovery from European public institutions and biotechs from 9 EU countries together with top Australian and Canadian groups and US collaborators, have agreed to join forces in EAVI, providing a pool of international expertise at the highest level. EAVI2020 will provide a platform for the discovery and selection of several new, diverse and novel preventive and/or therapeutic vaccine candidates for HIV/AIDS. Emphasis will be placed on early rapid, iterative, small Experimental medicine (EM) human vaccine studies to select and refine the best immunogens, adjuvants, vectors, homologous and heterologous prime–boost schedules, and determine the impact of host factors such as gender and genetics. Animal models will be used to complement human studies, and to select novel immunization technologies to be advanced to the clinic. To shift the “risk curve” in product development we will develop innovative risk prediction methods, specifically designed to reduce the risk associated with late stage preventive or therapeutic vaccine failure, increasing the chance of discovery of an effective vaccine.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

Address

South Kensington Campus Exhibition Road
Sw7 2az London

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 6 122 541,25

Participants (25)

Sort alphabetically

Sort by EU Contribution

Expand all

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 2 300 415

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE

France

EU Contribution

€ 1 140 062,50

FUNDACIO PRIVADA INSTITUT DE RECERCA DE LA SIDA-CAIXA

Spain

EU Contribution

€ 1 998 031,25

ISTITUTO SUPERIORE DI SANITA

Italy

EU Contribution

€ 389 700

POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH

Austria

EU Contribution

€ 3 449 000

FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA

Spain

EU Contribution

€ 629 000

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Netherlands

EU Contribution

€ 571 500

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

France

EU Contribution

€ 1 390 635

OSPEDALE SAN RAFFAELE SRL

Italy

EU Contribution

€ 669 938,75

UNIVERSITE JOSEPH FOURIER GRENOBLE 1

France

UNIVERSITE GRENOBLE ALPES

France

EU Contribution

€ 612 907,50

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 190 612,50

KAROLINSKA INSTITUTET

Sweden

EU Contribution

€ 895 561,25

UNIVERSITATSKLINIKUM ERLANGEN

Germany

EU Contribution

€ 564 021

THE UNIVERSITY OF WESTERN ONTARIO

Canada

NEMZETI ELELMISZERLANC-BIZTONSAGI HIVATAL

Hungary

EU Contribution

€ 211 298,75

LUDWIG BOLTZMANN GESELLSCHAFT GMBH

Austria

EU Contribution

€ 201 250

BIONTECH RNA PHARMACEUTICALS GMBH

Germany

EU Contribution

€ 371 375

INSTITUTO DE SALUD CARLOS III

Spain

EU Contribution

€ 403 828,75

STICHTING INTERNATIONAL AIDS VACCINE INITIATIVE THE NETHERLANDS

Netherlands

UNIVERSITY OF MELBOURNE

Australia

UNIVERSITY OF NEW SOUTH WALES

Australia

GENOME RESEARCH LIMITED

United Kingdom

INTERNATIONAL AIDS VACCINE INITIATIVE INC

United States

EU Contribution

€ 626 000

UNIVERSITY OF SOUTHAMPTON

United Kingdom

EU Contribution

€ 210 343,75

Project information

Grant agreement ID: 681137

Status

Ongoing project

  • Start date

    1 November 2015

  • End date

    31 October 2020

Funded under:

H2020-EU.3.1.2.

  • Overall budget:

    € 24 088 765

  • EU contribution

    € 22 948 022,25

Coordinated by:

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom